Loading provider…
Loading provider…
Internal Medicine Physician in Salt Lake City, UT
NPI: 1437210556HQ Phone
Get M.D., PH.D. Nelson's Phone Numberphone_androidMobile
Get M.D., PH.D. Nelson's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMD State Medical License
Lead Sponsor: Sanofi Pasteur, a Sanofi Company
Intervention / Treatment: BIOLOGICAL: Placebo, BIOLOGICAL: CYD Dengue Vaccine, BIOLOGICAL: Inactivated rabies virus vaccine
Lead Sponsor: Sanofi Pasteur, a Sanofi Company
Collaborators: GlaxoSmithKline
Intervention / Treatment: BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03, BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4
Lead Sponsor: Sanofi Pasteur, a Sanofi Company
Intervention / Treatment: BIOLOGICAL: Placebo, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination